Elicio Therapeutics, Inc.
ELTX
$11.68
-$0.50-4.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.96% | -4.15% | 12.43% | 10.29% | -14.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.39% | -22.23% | -7.63% | 4.83% | 43.48% |
| Operating Income | 34.39% | 22.23% | 7.63% | -4.83% | -43.48% |
| Income Before Tax | 44.89% | 46.48% | -46.09% | 5.23% | -56.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.89% | 46.48% | -46.09% | 5.23% | -56.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.89% | 46.48% | -46.09% | 5.23% | -56.49% |
| EBIT | 34.39% | 22.23% | 7.63% | -4.83% | -43.48% |
| EBITDA | 34.34% | 22.14% | 7.43% | -5.16% | -43.80% |
| EPS Basic | 51.49% | 56.45% | -2.65% | 24.82% | 2.07% |
| Normalized Basic EPS | 51.48% | 56.45% | -6.69% | 24.83% | 3.22% |
| EPS Diluted | 51.49% | 56.45% | -2.65% | 24.82% | 2.07% |
| Normalized Diluted EPS | 51.48% | 56.45% | -6.69% | 24.83% | 3.22% |
| Average Basic Shares Outstanding | 13.60% | 22.90% | 42.31% | 26.05% | 59.79% |
| Average Diluted Shares Outstanding | 13.60% | 22.90% | 42.31% | 26.05% | 59.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |